The opportunity to present original research, case series, case reports, and review articles to the San Diego Dermatology Symposium attendees is an integral part of the conference’s continuing education program. Encore abstracts/posters are permitted. We will allow posters with data that has already been published within the last 6 months, assuming that appropriate copyright permissions are obtained from the journal. Posters will be on display at the meeting on poster boards and will be available on the SDDS website until August 31, 2025.
There are three poster categories: Posters
Top Poster Competition
Fee: $125 per poster
Eligible to enter: Medical students, residents, fellows and dermatologists who graduated in 2022-2024
All posters are to be submitted electronically via the San Diego Dermatology Symposium website by Sunday, January 19, 2025. Digital posters must be formatted to 1920 W x 1080 H in size, landscape orientation and in PDF format.
All submissions will be reviewed and accepted based on scientific value and educational need. Accepted poster submissions will be posted on the SDDS website until August 31, 2025.
Top poster recipients will be notified and invited to present at the 2025 San Diego Dermatology Symposium no later than Friday, January 25, 2025.
The top posters will be selected for a short oral presentation during a 60-minute poster session on the afternoon of Friday, February 7, 2025. *Please do not bring a physical poster to the conference. You will present at the podium with a power point presentation only.*
If you are selected and invited to attend the SDDS program as a top poster, at least one author of the poster must register for the conference as well as attend in-person. Travel expenses are the responsibility of the author.
e-Poster
e-Posters are posted online on the website only.
Fee: $75 per poster
Eligible: Medical Students only
Please allow up to 1 week from date of submission for notification of approval or denial.
E-posters are not eligible for a top poster presentation, and medical students who submit an e-poster are not eligible to register for the symposium.
All submissions will be reviewed and accepted based on scientific value and educational need. Accepted poster submissions will be posted on the SDDS website until August 31, 2025.
Industry Poster
Fee: $800.
Not eligible for top poster presentation at conference.
Submission of an industry poster constitutes a commitment for at least one author to register and attend the conference. For the industry poster break on Saturday morning, at least one author for each industry poster must be present and stand next to the poster during this break.
Industry Poster Printing Guidelines: Authors are responsible for printing their poster boards on a foam core sign. Posters must be printed on foam core, 48 W x 36 H in size (landscape).
Poster by attending physician/NP/PA
Fee: $500
Not eligible for top poster presentation at conference.
There are three poster categories: Posters
Top Poster Competition
Fee: $125 per poster
Eligible to enter: Medical students, residents, fellows and dermatologists who graduated in 2022-2024
All posters are to be submitted electronically via the San Diego Dermatology Symposium website by Sunday, January 19, 2025. Digital posters must be formatted to 1920 W x 1080 H in size, landscape orientation and in PDF format.
All submissions will be reviewed and accepted based on scientific value and educational need. Accepted poster submissions will be posted on the SDDS website until August 31, 2025.
Top poster recipients will be notified and invited to present at the 2025 San Diego Dermatology Symposium no later than Friday, January 25, 2025.
The top posters will be selected for a short oral presentation during a 60-minute poster session on the afternoon of Friday, February 7, 2025. *Please do not bring a physical poster to the conference. You will present at the podium with a power point presentation only.*
If you are selected and invited to attend the SDDS program as a top poster, at least one author of the poster must register for the conference as well as attend in-person. Travel expenses are the responsibility of the author.
e-Poster
e-Posters are posted online on the website only.
Fee: $75 per poster
Eligible: Medical Students only
Please allow up to 1 week from date of submission for notification of approval or denial.
E-posters are not eligible for a top poster presentation, and medical students who submit an e-poster are not eligible to register for the symposium.
All submissions will be reviewed and accepted based on scientific value and educational need. Accepted poster submissions will be posted on the SDDS website until August 31, 2025.
Industry Poster
Fee: $800.
Not eligible for top poster presentation at conference.
Submission of an industry poster constitutes a commitment for at least one author to register and attend the conference. For the industry poster break on Saturday morning, at least one author for each industry poster must be present and stand next to the poster during this break.
Industry Poster Printing Guidelines: Authors are responsible for printing their poster boards on a foam core sign. Posters must be printed on foam core, 48 W x 36 H in size (landscape).
Poster by attending physician/NP/PA
Fee: $500
Not eligible for top poster presentation at conference.
Poster Submission Rules & Guidelines
All posters are due by 11:59pm Pacific Time on January 19, 2025. After this date/time, the submissions site will close automatically and can no longer accept submissions. There will be no exceptions to this policy.
There is no limit on the number of posters a company/person may submit.
Payment is required upon submission of the form.
Posters fees are non-refundable.
Pricing is available if interested in additional features such as uploading to the SDDS website audio slides, audio files/commentaries, and author videos.
Content: Inclusion of graphs, tables and other visuals is strongly recommended to enhance engagement. Include all authors and affiliations. All authors must disclose financial relationships. One original author of a poster is required to register for the symposium. If you have multiple posters, each poster must have a unique author registered for the symposium.
Commercialism: Any display at the San Diego Dermatology Symposium in which cost is underwritten by a pharmaceutical company or other entity must avoid commercialism. Drugs, instrumentation, or devices must not use brand names. If such situations occur, the author/exhibitor is responsible for identifying and clearly stating on the poster that a portion or portions of the cost were provided by the commercial company named.
Brand Names: Generic or scientific names of drugs/devices should be used in place of brand names. If brand name is necessary to understand poster content, it should be used only once (after the first mention of the drug or device’s name). Pharmaceutical or other support of any study should be acknowledged at the end of the poster.
Copyright: Copyright is shared. The Dermatology Research and Education Foundation owns copyright for its own use. Author(s) retain the rights for all other uses.
Note to poster submitters: if a poster is accepted (including oral presentations), travel is your own responsibility and not reimbursed by the symposium.
All posters are due by 11:59pm Pacific Time on January 19, 2025. After this date/time, the submissions site will close automatically and can no longer accept submissions. There will be no exceptions to this policy.
There is no limit on the number of posters a company/person may submit.
Payment is required upon submission of the form.
Posters fees are non-refundable.
Pricing is available if interested in additional features such as uploading to the SDDS website audio slides, audio files/commentaries, and author videos.
Content: Inclusion of graphs, tables and other visuals is strongly recommended to enhance engagement. Include all authors and affiliations. All authors must disclose financial relationships. One original author of a poster is required to register for the symposium. If you have multiple posters, each poster must have a unique author registered for the symposium.
Commercialism: Any display at the San Diego Dermatology Symposium in which cost is underwritten by a pharmaceutical company or other entity must avoid commercialism. Drugs, instrumentation, or devices must not use brand names. If such situations occur, the author/exhibitor is responsible for identifying and clearly stating on the poster that a portion or portions of the cost were provided by the commercial company named.
Brand Names: Generic or scientific names of drugs/devices should be used in place of brand names. If brand name is necessary to understand poster content, it should be used only once (after the first mention of the drug or device’s name). Pharmaceutical or other support of any study should be acknowledged at the end of the poster.
Copyright: Copyright is shared. The Dermatology Research and Education Foundation owns copyright for its own use. Author(s) retain the rights for all other uses.
Note to poster submitters: if a poster is accepted (including oral presentations), travel is your own responsibility and not reimbursed by the symposium.
Industry Posters
Sequence of Improvement of Signs, Symptoms, and Quality of Life in Patients With Prurigo Nodularis Receiving Dupilumab
Brian S. Kim1, Sonja Ständer2, H. Chih-ho Hong3,4, Hiroyuki Murota5, Amy Praestgaard6, Joseph Zahn7, Simmi Wiggins8
Fixed‑Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% vs Adapalene 0.3%/Benzoyl Peroxide 2.5% Gels for Moderate to Severe Acne: Comparative Patient Journey
Lawrence Green, MD; Leon H. Kircik, MD; Julie C. Harper, MD; Hilary Baldwin, MD; Neil Bhatia, MD; Zoe D. Draelos, MD; Lawrence Eichenfield, MD; Ted Lain, MD, MBA; William P. Werschler, MD; Karol Wroblewski, PharmD; Eric Guenin, PharmD, PhD, MPH
Lawrence Green, MD; Leon H. Kircik, MD; Julie C. Harper, MD; Hilary Baldwin, MD; Neil Bhatia, MD; Zoe D. Draelos, MD; Lawrence Eichenfield, MD; Ted Lain, MD, MBA; William P. Werschler, MD; Karol Wroblewski, PharmD; Eric Guenin, PharmD, PhD, MPH
Dupilumab Significantly Improves Itch and Urticaria Activity in Patients with Chronic Spontaneous Urticaria (CUPID STUDY C)
Thomas B. Casale1, Sarbjit S. Saini2, Jonathan A. Bernstein3, Ana M. Giménez-Arnau4, Deborah Bauer5, Nikhil Amin6, Lacey B. Robinson7, Paula Dakin6, Elizabeth Laws7, Allen Radin6, Melanie Makhija7
Thomas B. Casale1, Sarbjit S. Saini2, Jonathan A. Bernstein3, Ana M. Giménez-Arnau4, Deborah Bauer5, Nikhil Amin6, Lacey B. Robinson7, Paula Dakin6, Elizabeth Laws7, Allen Radin6, Melanie Makhija7
Clinical use of the i31-GEP for SLNB for T1-T2a cutaneous melanoma significantly and safely reduces unnecessary procedures
Timothy Beard, MD, Stanley P. Leong, MD, Rajan P. Kulkarni, MD, Brian Martin, PhD, Kelli Ahmed, PhD, Andrew Ward, PhD, Rohit Sharma, MD, J. Michael Guenther, MD, Shawn Young, MD
Timothy Beard, MD, Stanley P. Leong, MD, Rajan P. Kulkarni, MD, Brian Martin, PhD, Kelli Ahmed, PhD, Andrew Ward, PhD, Rohit Sharma, MD, J. Michael Guenther, MD, Shawn Young, MD
Efficacy and Safety of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Older Adults
Shari R. Lipner, MD, PhD; Aditya Gupta, MD, PhD; Warren S. Joseph, DPM; Boni Elewski, MD; Eric Guenin, PharmD, PhD, MPH; Tracey C. Vlahovic, DPM
Shari R. Lipner, MD, PhD; Aditya Gupta, MD, PhD; Warren S. Joseph, DPM; Boni Elewski, MD; Eric Guenin, PharmD, PhD, MPH; Tracey C. Vlahovic, DPM
THE POWER OF IMAGERY IN CLINICAL MEDICINE: LEVERAGING CLINICAL PHOTOS FROM THE VISIBLE STUDY TO FOSTER CONVERSATIONS BETWEEN CLINICIANS AND PATIENTS
AO Rodriguez, MD; LS Gold, MD; M Shahriari, MD; A Alexis, MD, MPH; O Choi, MD, PhD; D Chan, PhD; T Alkousakis, MD; E Skobelev, PharmD; S Ramji, PharmD; OS Barrero, PhD; A McMichael, MD; SC Taylor, MD; SR Desai, MD
AO Rodriguez, MD; LS Gold, MD; M Shahriari, MD; A Alexis, MD, MPH; O Choi, MD, PhD; D Chan, PhD; T Alkousakis, MD; E Skobelev, PharmD; S Ramji, PharmD; OS Barrero, PhD; A McMichael, MD; SC Taylor, MD; SR Desai, MD
Sustained Improvements in Psoriasis Area and Severity Index and in Percent Body Surface Area of Psoriasis With JNJ-77242113 in Patients With Moderate-to-Severe Plaque Psoriasis: Treat-to-Target Analyses in the FRONTIER 1 & 2 Studies
K. Papp: MD, PhD; L. Ferris: MD, PhD; A. Pinter: MD; P. Rich: MD; R. Vender: MD; A Pink: PhD; T. Ota: MD, PhD; Y-K Shen: PhD; S. Li: PhD; A. DeLozier: PhD; O Salgado: PhD; Y-W Yang: MD, MS; R. Bissonnette: MD
K. Papp: MD, PhD; L. Ferris: MD, PhD; A. Pinter: MD; P. Rich: MD; R. Vender: MD; A Pink: PhD; T. Ota: MD, PhD; Y-K Shen: PhD; S. Li: PhD; A. DeLozier: PhD; O Salgado: PhD; Y-W Yang: MD, MS; R. Bissonnette: MD
Top Posters
Two Primary Melanoma In Situ Lesions of the Vulva
Bianca N. Coffel, MD; David W. L. Cowart, MD
Bianca N. Coffel, MD; David W. L. Cowart, MD
Rapidly Progressive Angioinvasive Mucormycosis in a Pediatric Patient
Nickoulet Babaei BS, Amylee Sam MD
Nickoulet Babaei BS, Amylee Sam MD
Diagnostic Accuracy of Public AI Tools in Dermatology: A Cross-Sectional Analysis Across Skin Tones
Mireya Cervantes BS, Seanna Yang BS, Minka Gill BS, Dahyeon Kim BS, Nickoulet Babaei BS, Jashin J. Wu MD
Mireya Cervantes BS, Seanna Yang BS, Minka Gill BS, Dahyeon Kim BS, Nickoulet Babaei BS, Jashin J. Wu MD
Risk Factors for Surgical Site Infections in Secondary Intention Wounds After Mohs Micrographic Surgery
Geena Conde BS, Amanda Rosenthal MD, Margit Juhasz MD, Nima M Gharavi MD PhD
Geena Conde BS, Amanda Rosenthal MD, Margit Juhasz MD, Nima M Gharavi MD PhD
Association Between Hidradenitis Suppurativa and PCOS in the All of Us Database
Minka Gill, BS, Nickoulet Babaei, BS, Dahyeon Kim, BS, Mireya Cervantes, BS, Seanna Yang, BS, Dr. Jashin Wu, MD
Minka Gill, BS, Nickoulet Babaei, BS, Dahyeon Kim, BS, Mireya Cervantes, BS, Seanna Yang, BS, Dr. Jashin Wu, MD
Linear Immunoglobulin A Bullous Dermatosis of Childhood Mimicking Bullous Tinea Infection
Halen Heussner, BSc; Travis Lam, DO; Tracy Middleton, DO
Halen Heussner, BSc; Travis Lam, DO; Tracy Middleton, DO
Off-Label Anti-IL-17A Biologic Regimens in Psoriasis: A Systematic Review
Dahyeon Kim, B.S., Nickoulet Babaei, B.S., Mireya Cervantes, B.S., Minka Gill, B.S., Seanna Yang, B.S., Dr. Jashin Wu, M.D.
Dahyeon Kim, B.S., Nickoulet Babaei, B.S., Mireya Cervantes, B.S., Minka Gill, B.S., Seanna Yang, B.S., Dr. Jashin Wu, M.D.
Refractory Acrodermatitis Continua of Hallopeau in a Pediatric Patient: Unveiling Underlying Mixed Connective Tissue Disorder
Nadine Del Rosario, BS, Shayla Nguyen, BS
Nadine Del Rosario, BS, Shayla Nguyen, BS
Case of Rapidly Growing and Regressing Squamous Cell-Like Cutaneous Tumors of the Face and Scalp
Samantha N. Scerbo, MPH; Raj P. Fadadu, MD, MS; Laura S. Romero, MD
Samantha N. Scerbo, MPH; Raj P. Fadadu, MD, MS; Laura S. Romero, MD
Sleep disturbances and associated psychiatric comorbidities in atopic dermatitis: a systematic review
Sheila Sharifi BA, Isabella J. Tan BS, Mohammed Jafferany MD
Sheila Sharifi BA, Isabella J. Tan BS, Mohammed Jafferany MD
A Man with Pruritus and a Violaceous Rash: Blastic Plasmacytoid Dendritic Cell Neoplasm
Joseph Aleshaki, DO | Marissa Yaldo, MS3 | Elizabeth Keiser, MD | Taylor Deal, MD | Sama Carley, MD
Joseph Aleshaki, DO | Marissa Yaldo, MS3 | Elizabeth Keiser, MD | Taylor Deal, MD | Sama Carley, MD
Medical Students E-Posters
School-Based Sun Safety in the United States
Vera Wang, BA
Vera Wang, BA
Analyzing Diversity of Skin Color in Neonatal Textbooks for Nurse Practitioner Education
Dillon Stevens, Adriene Pavek, Anabelle Hunstman, Justin Lyon, Zachary Ney, Dallin Ringwood, Meg Takara, Dr. Kim Friddle, Phd, *Dr. Jennifer Hamilton, DNP
Dillon Stevens, Adriene Pavek, Anabelle Hunstman, Justin Lyon, Zachary Ney, Dallin Ringwood, Meg Takara, Dr. Kim Friddle, Phd, *Dr. Jennifer Hamilton, DNP
Never Ignore Benign Fibrofolliculomas- A Case of Genodermatosis
Milan Mahesh, BS, Rajeeve Thachil, MD
Milan Mahesh, BS, Rajeeve Thachil, MD
Refractory Acrodermatitis Continua of Hallopeau in a Pediatric Patient: Unveiling Underlying Mixed Connective Tissue Disorder
Nadine Del Rosario BS, Shayla Nguyen, Ethan Nguyen, MD
Nadine Del Rosario BS, Shayla Nguyen, Ethan Nguyen, MD
Dupilumab in Uremic Pruritus: A Novel Treatment Option
Colin Burnette B.S., Marissa Ruppe B.A., Peter Mattei M.D.
Colin Burnette B.S., Marissa Ruppe B.A., Peter Mattei M.D.
Silent Blisters: Heparin-Induced Subcorneal Hemorrhagic Lesions Without Systemic Symptoms
Hannah Gandy, BS, Alexis Antonucci, BS, Milaan Shah, MD, Andraia Li, MD, Richard Marchell, MD
Hannah Gandy, BS, Alexis Antonucci, BS, Milaan Shah, MD, Andraia Li, MD, Richard Marchell, MD
Disparities in Angioedema Hospitalizations: The Role of Race, Income and Geographic Region
Sumra Din, MBS, Mashal Zaide, BSc, Sara Omari, BSc, Haider Ismail, MBBS
Sumra Din, MBS, Mashal Zaide, BSc, Sara Omari, BSc, Haider Ismail, MBBS
A Case of Refractory Darier Disease Responsive to Apremilast
Carol Stegura, MEng; Hannah Neimy BS; Alan Snyder, MD; Richard Marchell, MD
Carol Stegura, MEng; Hannah Neimy BS; Alan Snyder, MD; Richard Marchell, MD
Blastic Plasmacytoid Dendritic Cell Neoplasm: A Deadly Diagnosis
Romina Garakani, Zane Sejdiu, Kelly McCoy, Laura Huang, Farhaan Hafeez
Romina Garakani, Zane Sejdiu, Kelly McCoy, Laura Huang, Farhaan Hafeez
Pediatric Amelanotic Blue Nevus: A Diagnostic Challenge
Zane Sejdiu BS, Romina Garakani BS, Kelly McCoy MD, Farhaan Hafeez MD, Andrew C Krakowski MD
Zane Sejdiu BS, Romina Garakani BS, Kelly McCoy MD, Farhaan Hafeez MD, Andrew C Krakowski MD
Eosinophilic Dermatosis of Hematologic Malignancy
Raveena Ghanshani MS, Grace Chan MD, Brittney DeClerck MD, Gene H. Kim MD, Ashley B. Crew MD, Jennifer L. Hsiao MD
Raveena Ghanshani MS, Grace Chan MD, Brittney DeClerck MD, Gene H. Kim MD, Ashley B. Crew MD, Jennifer L. Hsiao MD
Friend or Foe: A Systematic Review of Dupilumab and Alopecia Areata
Madison G. Romanski, BS; Anagha Srivatsa, BS; Wasey Rehman, BS; Shaveonte Graham, MD; Rafey Rehman, MD; Meena Moossavi, MD; Darius Mehregan, MD
Madison G. Romanski, BS; Anagha Srivatsa, BS; Wasey Rehman, BS; Shaveonte Graham, MD; Rafey Rehman, MD; Meena Moossavi, MD; Darius Mehregan, MD
Surgical Resection Outcomes in the Treatment of Paraneoplastic Autoimmune Multiorgan Syndrome (PAMS)
Vy X. Pham, B.A., Jeffrey Chen, B.S., Reid Oldenburg, M.D., Ph.D.
Vy X. Pham, B.A., Jeffrey Chen, B.S., Reid Oldenburg, M.D., Ph.D.
Disparities in Melanoma Incidence Between Sex and Age Populations in the United States Between 2001 and 2021
Rita Kamoua, BS, Christina B. Miles, MD, Julian Trevino, MD
Rita Kamoua, BS, Christina B. Miles, MD, Julian Trevino, MD
Dermatologic Manifestations in Crohn’s Disease: A Comparative Analysis of Gender and Racial Differences
Luke Hamilton, BS, Danielle Miller, BA, Amina El Ayadi, PhD, Juquan Song, MD, Michael Wilkerson, MD
Luke Hamilton, BS, Danielle Miller, BA, Amina El Ayadi, PhD, Juquan Song, MD, Michael Wilkerson, MD
Real-World Analysis of Dermatologic Manifestations Associated with GLP-1 Agonist Use for Weight Loss in Non-Diabetic Obese Adults
Danielle Miller, B.A., Luke Hamilton, B.S., Amina El Ayadi, PhD, Juquan Song, M.D., Michael Wilkerson, M.D.
Danielle Miller, B.A., Luke Hamilton, B.S., Amina El Ayadi, PhD, Juquan Song, M.D., Michael Wilkerson, M.D.
A Diagnostic Puzzle: A Case of Systemic Sclerosis Associated with Immunotherapy for Metastatic Melanoma
Penny Smith, MS; Hannah Neimy, BS; Hannah Gandy, BS, Mary Nan Leath, BS, Shelby Smith, BS, Pelin Sagut, MD/MSCR, Kathryn Lynam, MD; Jane Scribner, MD
Penny Smith, MS; Hannah Neimy, BS; Hannah Gandy, BS, Mary Nan Leath, BS, Shelby Smith, BS, Pelin Sagut, MD/MSCR, Kathryn Lynam, MD; Jane Scribner, MD
Skin-picking disorder: an update on pharmacologic treatment in adults
Nina Modanlo, MHS; Xiaofeng Yan, MD, PhD; James Bourgeois, OD, MD
Nina Modanlo, MHS; Xiaofeng Yan, MD, PhD; James Bourgeois, OD, MD
An evidence-based review on the role of antidiabetic drugs in autoimmune disorders and the potential use of antidiabetic drugs in vitiligo
Seanna Yang, B.S.1, Dahyeon Kim, B.S.2, Nickoulet Babaei, B.S.2, Mireya Cervantes, B.S.3, Minka Gill, B.S.4, Jashin J. Wu, M.D.5
Seanna Yang, B.S.1, Dahyeon Kim, B.S.2, Nickoulet Babaei, B.S.2, Mireya Cervantes, B.S.3, Minka Gill, B.S.4, Jashin J. Wu, M.D.5
Reduced Injection Site Pain with Altered pH in 24-Hour Reconstituted Botulinum Toxin: Findings from a Randomized Controlled Study on Cosmetic Application
Kenan Kherallah (BS), Mohammed G Turkmani (MD), Nabil Fakih-Gomez (MD), Cristina Munoz- Gonzalez (MD)
Kenan Kherallah (BS), Mohammed G Turkmani (MD), Nabil Fakih-Gomez (MD), Cristina Munoz- Gonzalez (MD)